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Abstract
Background: the number and proportion of adults diagnosed with HIV infection aged 50 years and older has risen. This
study compares the effect of CD4 counts and anti-retroviral therapy (ART) on mortality rates among adults diagnosed aged
≥50 with those diagnosed at a younger age.
Methods: retrospective cohort analysis of national surveillance reports of HIV-diagnosed adults (15 years and older) in
England, Wales and Northern Ireland. The relative impacts of age, CD4 count at diagnosis and ART on mortality were
determined in Cox proportional hazards models.
Results: among 63,805 adults diagnosed with HIV between 2000 and 2009, 9% (5,683) were aged ≥50 years; older
persons were more likely to be white, heterosexual and present with a CD4 count <200 cells/mm3 (48 versus 32%
P < 0.01) and AIDS at diagnosis (19 versus 9%, P < 0.01). One-year mortality was higher in older adults (10 versus 3%,
P < 0.01) and especially in those diagnosed with a CD4 <200 cells/mm3 left untreated (46 versus 15%, P< 0.01). While
the relative mortality risk reduction from ART initiation at CD <200 cells/mm3 was similar in both age groups, the abso-
lute risk difference was higher among older adults (40 versus 12% fewer deaths) such that the number needed to treat older
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adults to prevent one death was two compared with eight among younger adults.
Conclusions: the magnitude of beneﬁt from ART is greater in older adults than younger adults. Older persons should be
considered as a target for HIV testing. Coupled with prompt treatment, earlier diagnosis is likely to reduce substantially
deaths in this group.
Keywords: HIV, AIDS, antiretroviral therapy, epidemiology, surveillance, older people
Introduction
Since 2000, the HIV epidemic in the UK has been charac-
terised by a re-emergence of infections among men who have
sex with men (MSM), in common with other European coun-
tries, North America and Australia [1]. This has coincided with
an increase in heterosexual transmissions, the majority of
which were acquired in sub-Saharan Africa [2]. Surveillance
data also show a clear increase in new diagnoses among
persons aged ≥50 years [3]. In England, Wales and Northern
Ireland, the number of older adults diagnosed with HIV
increased from 299 in 2000 (8%) to 807 in 2009 (13%) [4].
Furthermore, older adults are more likely to present with
advanced disease, with 48% diagnosed with a CD4 count
<200 cells/mm3 at diagnosis [5]. Similar increases in HIV diag-
noses among older adults have been reported in the USA [6].
The increasing trend in new diagnoses of HIV among
older adults suggests an under-recognised public health
problem. There is evidence that older adults presenting
later are associated with poor outcomes [2, 3].
Consequently, aggressive antiretroviral therapy (ART) may
often be required at diagnosis [7]. While older age in itself
should not inﬂuence ART initiation, ART use is made
more challenging by the increased prevalence of co-
morbidities in this age group [8, 9]. From a public health
perspective, late diagnoses among older adults suggest a
longer period of untreated HIV. This has implications for
continued transmission while infection remains undiag-
nosed. It is also possible that lower CD4 in older adults at
diagnosis reﬂects more rapid disease progression [10, 11].
Using data from a large national cohort of HIV diag-
nosed individuals, this study set out to determine ART
coverage and mortality rates among older HIV positive
adults, and make comparisons with younger HIV diagnosed
adults. We hypothesised that mortality might be different in
older adults due to differences in CD4 count at presenta-
tion, ART initiation, response to ART or a combination of
these factors.
Methods
Design
A retrospective cohort analysis of new HIV diagnoses
reported to the Health Protection Agency (HPA) between
2000 and 2009 was conducted. National surveillance data
from England, Wales and Northern Ireland receive infor-
mation from multiple sources reﬂecting the full range of
care provision: (i) clinician reports of new HIV diagnoses,
ﬁrst AIDS diagnosis, and deaths among HIV-diagnosed
adults; (ii) laboratory reports of CD4 surveillance [12]; (iii)
a national cohort of all outpatient care providers with
annual follow-up [13]. Reports of death from any cause are
also cross-referenced by mortality information from the
Ofﬁce for National Statistics (ONS). Data were linked
across systems using soundex codes, sex and date of birth
with records linked in 92%. Full details of the methodology
for these surveillance systems are published on the HPA
website [14].
Participants
All HIV seropositive adults aged 15 years and over, diag-
nosed in England, Wales and Northern Ireland between
2000 and 2009, were included. Exposure route, ethnicity
and development of AIDS were determined by clinician
report at diagnosis. Information on CD4 count at diagnosis
was available from laboratory reports [12] and new diagno-
sis reports. Persons were considered as having used ART if
information on nucleoside and nucleotide reverse tran-
scriptase inhibitors, non-nucleoside reverse transcriptase
inhibitors or protease inhibiters were reported in survey
data from outpatient care providers at any time. Prescribing
information among patients accessing outpatient care is
near-complete. In 2011, 0.38% (283 of 73,659) records had
missing data [15]. CD4 count within 91 days of diagnosis
deﬁned ‘late’ diagnoses (CD4 <350 cells/mm3) and ‘very
late’ diagnoses (CD4 <200 cells/mm3) [16]. Though
current guidelines recommend initiating therapy at CD4
<350 cells/mm3, we considered ‘very late’ diagnoses and
‘late’ diagnoses separately because CD4 <200 cells/mm3
was regarded as the treatment threshold during the earlier
part of the time period 2000–09.
Outcome measures
Mortality was obtained from clinician reports, supplemen-
ted by ONS reports. Short-term mortality was deﬁned as
death from any cause within 1 year of HIV diagnosis.
These reports were followed up until December 2010.
Data analysis
All data were analysed in STATA version 11.1. (Stata Corp,
TX, USA). The effect of age on all-cause mortality within
1 year from diagnosis was examined stratiﬁed in 10-year
521
Early diagnosis and treatment of HIV infection
age groups. Univariable and multivariable Cox proportional
hazards models were used, assessing the effects of sex, eth-
nicity and exposure route. Individuals not identifying as
black or white were classiﬁed as ‘other’. Persons reporting
intravenous drug use (IDU) as possible route of infection
were considered together, even if they also reported other
possible exposures (e.g. MSM).
Hazard ratios (HRs) were calculated with 95% conﬁ-
dence intervals (CIs). Post-model testing included the
examination of Schoenfeld residuals and log–log survival
plots. The assumption of proportionality did not hold for
the population as a whole, though were met after stratiﬁca-
tion by sex and exposure. Accordingly, three models esti-
mating the effect of age and ethnicity are presented: MSM;
heterosexual men; heterosexual women. Exposure through
IDU was not considered further due to the relatively small
number of older individuals in this group (n = 65).
The effect of ART use on 1-year mortality was assessed
in a series of proportional hazards models, where adults
aged 15–49 (‘young’) and age ≥50 years (‘older’) were com-
pared. ART initiation in late diagnoses and very late diagno-
ses were modelled separately. Differences in Kaplan–Meier
plots were determined by the log-rank test. The χ2 test was
applied to test differences in proportions and the Mann–
Whitney U test to assess differences in variables with a
non-Gaussian distribution. For mortality, we calculated the
relative risk reduction, risk difference and number needed
to treat (NNT), which was calculated as the inverse of the
risk difference associated with ART use [17].
The effect of missing data was investigated by separately
examining mortality and clinical AIDS at diagnosis for
persons with an unknown CD4 count at diagnosis and for
those not subsequently entering outpatient care.
Results
Between 2000 and 2009, 63,805 adults were newly diag-
nosed with HIV, of which 5,683 diagnoses were in adults
≥50 years (9%). Of these diagnoses in older persons, 217
were aged ≥70 (4%) and the oldest diagnosed was aged 84.
Table 1 summarises the demographic and clinical character-
istics of these two age groups. Compared with younger
adults, older men were more likely to be white (58 versus
39%, P< 0.01) and heterosexual (31 versus 21%, P < 0.01).
Data on CD4 count at diagnosis were available for
48,144 (75%) of all participants (Table 1). Demographic in-
formation was similar for those with and without a CD4
count. Older persons had lower median CD4 counts (210
cells/mm3 versus 310 cells/mm3, P < 0.01) and more likely
to have an AIDS-deﬁning condition at ﬁrst diagnosis (19
versus 9%, P < 0.01), regardless of CD4 count. One-year
mortality was reported among 2,072 newly HIV diagnosed
adults; 1,515 in younger adults (3%) and 557 in older
adults (10%) (P < 0.01).
Table 2 shows the results of the multivariate Cox pro-
portional hazards regression for mortality within 1 year,
adjusted for age and ethnicity stratiﬁed by sex and exposure
route. The effect of age in different 10-year strata increased
and this was most evident in the MSM model. Compared
with adults aged 15–29, adults aged ≥60 had a higher mor-
tality (HR: 28; 95% CI: 18–45) in MSM, where the differ-
ence was less pronounced among heterosexually-acquired
infections (HR: 7.2; 95% CI: 4.6–11, men; HR: 11; 95%
CI: 7.5–17, women). Ethnicity did not appear to be a sig-
niﬁcant determinant of mortality, and no assessment of the
interaction between age and ethnicity was made.
The ﬁgure in Supplementary data available in Age and
Ageing online shows Kaplan–Meier plots for 1-year mortal-
ity stratiﬁed by CD4 count at diagnosis (CD4 >500; CD4
350–499; CD4 200–349; CD4 <200 cells/mm3), where
older and younger age groups were compared. Though
lower CD4 counts showed higher mortality, the largest dif-
ference is in the CD4 <200 cells/mm3 stratum (P < 0.01),
and this was even greater in the older age group (13% mor-
tality within 1 year).
The table in Supplementary data available in Age and
Ageing online shows the effect of ART on survival. Among
very late presenters (CD4 <200 cells/mm3), there was no
difference in ART use in older or younger adults (73 and
74%, respectively, P= 0.24). Mortality within 1 year of diag-
nosis in untreated persons was high in both age groups,
but much more so in older adults (Figure 1). Thus, 447 un-
treated younger adults (15%) and 186 untreated older
adults (46%) died within 1 year. The relative risk reduction
from ART initiation at CD <200 cells/mm3 was similar in
both age groups [younger RR 0.18 (95% CI: 0.15–0.21);
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Demographic and clinical characteristics of new
HIV diagnoses 2000–2009 in England, Wales and
Northern Ireland by age group
Age 15–49
(n= 58,122)
Age 50 and over
(n= 5,683)
P-value**
Median age men (IQR) 34 (29–40) 55 (52–60)
Median age women
(IQR)
31 (27–37) 55 (52–60)
Sex (% men) 34,437 (59) 4,189 (74) <0.01
Exposure route (%)
MSM 19,984 (34) 2,069 (36) <0.01
Heterosexual men 12,150 (21) 1,763 (31) <0.01
Heterosexual women 22,540 (39) 1,359 (24) <0.01
IDU 1,406 (2) 65 (1) <0.01
Other 2,042 (4) 427 (8)
Ethnic group (%)
White 22,860 (39) 3,305 (58) <0.01
Black 30,491 (52) 1,948 (34) <0.01
Other 4,771 (8) 430 (8)
One-year mortality (%) 1,515 (3) 557 (10) <0.01
AIDS at diagnosis (%)a 5,218 (9) 1,059 (19) <0.01
CD4 at diagnosis
performed (%)a
43,840 (75) 4,304 (76) 0.61
IQR, inter-quartile range.
aWithin 91 days.
**P-values calculated using χ2 tests.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Multivariable Cox regression model of proportional hazards for early mortality (1 year) in all new HIV diagnoses
between 2000 and 2007, stratified by sex
MSM Heterosexual men Heterosexual women
n HR (95% CI) n HR (95% CI) n HR (95% CI)
Age
15–29 5,439 1 2,371 1 8,477 1
30–39 8,015 2.3 (1.5–3.6) 5,751 2.0 (1.4–2.9) 9,489 2.1 (1.6–2.7)
40–49 4,509 6.7 (4.3–10) 3,318 2.5 (1.7–3.7) 3,410 4.5 (3.4–5.9)
50–59 1,465 13 (8.1–20) 1,161 5.0 (3.3–7.4) 972 4.2 (2.8–6.2)
60–69 512 28 (18–45) 484 7.2 (4.6–11) 312 11 (7.5–17)
Ethnicitya
White 18,581 1 2,831 1 2,620 1
Black 1,359 1.1 (0.7–1.7) 10,254 1.0 (0.8–1.3) 20,040 0.8 (0.1–1.0)
MSM, men who have sex with men.
aOther ethnicities not considered as a category in these models due to heterogeneity within this group.
Figure 1. Short-term mortality according to CD4 count at diagnosis and ART use. Each mortality curve is presented with upper
and lower 95% conﬁdence intervals. Upper panel shows mortality outcomes in the ﬁrst year from diagnosis when CD4 <200,
according to ART use. Lower panels show the same for CD4 200–349. Note the range on the y-axis is different (CD4 <200
from 0 to 0.4; CD4 200–349 from 0 to 0.15).
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older RR 0.12 (95% CI: 0.09–0.15)]. However, the absolute
risk difference was higher among older adults (12% fewer
deaths on treatment in younger versus 40% fewer deaths in
older adults on treatment). This larger absolute magnitude
of the effect of ART in older adults equates to a lower
number NNT (younger NNT = 8 versus older NNT = 2).
When a treatment threshold of CD4 <350 cells/mm3
was considered, proportionally more older adults received
ART (62 compared with 49% younger adults) (Figure 1).
The effect of ART in older adults also appeared to be
greater compared with younger adults treated at this CD4
level, though in neither group was the magnitude of beneﬁt
comparable with the effects at CD4 <200 cells/mm3.
One-year mortality and prevalence of AIDS deﬁning
conditions at diagnosis could be ascertained for the whole
cohort. These variables were used to assess differences in
persons without a CD4 at diagnosis (25%) or not entering
outpatient care (9%) (Supplementary data are available in
Age and Ageing online Table 2). Compared with the whole
cohort, no CD4 at diagnosis or not entering outpatient
care was associated with higher mortality. Those not enter-
ing outpatient care appeared to have a higher prevalence of
AIDS at diagnosis. Conversely, individuals subsequently re-
ceiving outpatient care had lower mortality than the cohort
as a whole.
Discussion
Between 2000 and 2009, adults aged 50 years or older
accounted for 9% of new diagnoses, and nearly half pre-
sented at a very late stage of HIV infection (CD4 <200
cells/mm3). Compared with younger adults, 1-year mortal-
ity was consistently higher in the older age group, but these
differences were signiﬁcantly larger in individuals presenting
very late. Given the higher mortality, the beneﬁt from ART
use in older persons was much greater compared with
younger adults (NNT in older 2 versus NNT in younger
8). Taken together, these results suggest that late diagnosis
is an important determinant of mortality in older adults.
Once HIV care is accessed, gains from treatment are
largest in this group. The proportion of late presentations,
coupled with the association of ART use with the highest
reductions in mortality among older adults strengthens the
case for speciﬁcally targeting older adults as a prevention
group.
Surveillance and cohort data have limitations. However,
surveillance methods available to HPA are well established,
and trends in all regions demonstrate little variation in the
short term. This stability in reporting suggests that case-
ascertainment is near-complete. Surveillance data may be
skewed by under-reporting of early deaths. To address po-
tential reporting delays, we included death reports to end of
2010 (among persons diagnosed to end of 2009). An add-
itional problem is the proportion of undiagnosed HIV,
though this study helps to highlight the likelihood of signiﬁ-
cant under-recognition in older persons. We were unable to
make an assessment of the inﬂuence of viral load on treat-
ment outcomes nor were we able to assess the effectiveness
of individual ART regimes in older persons, especially in
regard to co-morbidities. Further investigation at the clinic
level would be important.
It is clear that persons not linked into outpatient care, al-
though small in number, represent a group with more
advanced disease, with higher mortality and AIDS-deﬁning
conditions at diagnosis. These may include: patients lost to
follow-up for HIV care; individuals who could not be linked
across surveillance systems; those who present extremely late
and unwell and potentially die on ﬁrst admission with HIV.
Information on acute ART in persons with advanced infec-
tion, for example, hospitalised patients, might not be cap-
tured as effectively. If those apparently not receiving ART
were in fact treated, this would over-estimate the beneﬁt of
ART in the untreated groups. In any case, clinical reasons (e.
g. lack of provision or patient refusal) for why ART might
not have been initiated in this population were not available.
Though this is an important subgroup, it is unlikely that
further information on their treatment with ART would sub-
stantially alter the overall conclusions from the hazards
model.
The principal strength of this study is its near compre-
hensive coverage of persons diagnosed with HIV and acces-
sing HIV care in the ART era. Of all diagnosed cases, at
least 92% entered into outpatient care in our study. Reports
to HPA have been consistent across regions and over time.
The National Health Service provides virtually all HIV/
AIDS-related care, so linkage of new diagnoses for clinical
follow-up is a major advantage. Similarly, mortality reports
to ONS are a reliable notiﬁcation of outcomes. Previous
studies show very high rates of access to care and low rates
of loss to follow-up [18]. This does not appear to be differ-
ent for older adults. Indeed, older adults had comparable
proportions of CD4 performed at diagnosis and within
similar time frames.
The high mortality in relation to late diagnoses observed
in this national cohort is in keeping with other surveillance
data [19, 20]. It appears that when older adults eventually
present, more have an AIDS-deﬁning illness at diagnosis,
and it may be this clinical picture that triggers the initial
HIV test. Though older persons may be more likely to
adhere to ART [21], older individuals have a slower CD4
response to ART [22, 23]. However, we demonstrate here
for the ﬁrst time that the magnitude of beneﬁt from ART
is actually highest in older patients presenting very late.
The high number of late diagnoses in itself indicates a
signiﬁcant proportion of undiagnosed HIV in older adults.
Consequently, older adults are more often diagnosed on their
ﬁrst HIV test [24]. Older adults are more likely to be white
and heterosexual men compared with young people diag-
nosed with HIV and this identiﬁes a new demographic
for HIV infection in UK [3].
UK clinical guidelines have recommended starting
therapy at 350 cells/mm3 since 2008 with and a threshold
of 500 cells/mm3 currently under consideration [25] in line
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with US guidelines [26]. We note that data used in this
study (2000–09) show a larger proportion of older persons
received ART in the CD4 250–349 cells/mm3 range. This
may suggest that there was a greater degree of clinical
concern in older compared with younger persons.
Nonetheless, the magnitude of this response to ART was
still higher in older adults, though the effects are less pro-
nounced than for very late diagnoses. Because initiating
treatment at this threshold may indicate a selected group
that are clinically more unwell, the beneﬁt of ART is likely
to underestimate the absolute risk reduction were ARTs
given to the whole group at this CD4 threshold. Too few
persons were treated when CD4 was >350 cells/mm3 at
diagnosis to assess the effect of ART in this population.
HIV/AIDS is a treatable condition. Our ﬁndings
showing a high uptake rate of ART after diagnosis and a
high efﬁcacy of ART in older adults are encouraging.
Nevertheless older adults experience especially high rates of
mortality within 1 year of diagnosis, largely driven by late
diagnosis. There are broad public health implications for
older adults at risk of HIV. Wider testing in this population,
coupled with prompt treatment might substantially reduce
deaths among HIV-infected persons. Developing a testing
programme would be an important consideration, and in
some circumstances might be regarded as cost-effective [27].
Earlier diagnosis could perhaps be achieved if clinicians treat-
ing older adults contemplated testing more widely, perhaps
in the context of recurrent unexplained infections or being
mindful of sexual risk in older adults. Certainly, no routine
upper age limit should be regarded as appropriate to offer
HIV testing.
Key points
• Older adults being diagnosed with HIV are being recog-
nised very late.
• Accordingly, mortality is very high.
• As a result, the magnitude of beneﬁt from ART is just as
great.
• Earlier detection and prompt treatment is likely to miti-
gate some of the mortality from HIV in this age group.
Supplementary data
Supplementary data mentioned in the text is available to
subscribers in Age and Ageing online.
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